Iktos has announced a landmark multi-target strategic collaboration with Servier, an international independent pharmaceutical company governed by a foundation to accelerate the discovery of innovative small-molecule therapeutics. Under the terms of the agreement, which has a potential total value exceeding €1 billion, Iktos will deploy its AI-orchestrated discovery platform and robotics technology to design and optimize novel candidates across multiple undisclosed targets. By combining Iktos’ generative AI capabilities with Servier’s scientific and clinical expertise, the partnership aims to significantly reduce drug discovery timelines and improve candidate quality in key areas such as oncology and neurology, further solidifying Iktos’ position as a premier partner for AI-native pharmaceutical R&D.
